




PERSONAL INFORMATION

MAHMOUDREZA POURKARIM

 Herestraat, 49, Leuven 3000, Belgium

 +32-016-331153

 mahmoudreza.pourkarim@kuleuven.be
pourkarim1@yahoo.com

ORCID: 0000-0003-4620-6453

Research ID: M-9690-2018



CURRENT STATUS

****Senior Postdoctoral Research Fellow in Laboratory of Clinical and Epidemiological Virology, Rega Institute for Medical Research, KU Leuven, Belgium***

<https://rega.kuleuven.be/cev/mvr/lab-members>

****Visiting Professor of Shiraz University of Medical Sciences, Shiraz, Iran***

<http://gsia.sums.ac.ir/en/page/18598/Inbound-Visiting-Professors>

<http://gsia.sums.ac.ir/en/page/18604/Dr--Mahmoudreza-Pourkarim>

****Coronavirus Pandemic preparedness team of Institute for Future, KU Leuven***

https://rega.kuleuven.be/if/coronavirus_challenge

EDUCATION

2006–2012

PhD, in Virology

KU Leuven, Department of Microbiology and Immunology, Laboratory of Clinical and Epidemiological Virology

PhD thesis title: ***Genetic diversity and molecular evolution of Hepatitis B virus***

1993-1997

MSc. in Microbiology

Azad University of Jahrom, Iran

MSc. thesis title: ***Investigation of bacterial conjunctivitis in Boushehr province, Iran***

1989-1993

BSc. in Microbiology

Azad University of Kazeroun, Iran

EMPLOYMENT HISTORY

2000-2006

Iranian Blood Transfusion Organization (IBTO) of Boushehr, Iran

In charge of QC/ Ref lab of HIV/ HBV/ HCV

In charge of Research & Education

2001-2003

(IBTO) of Boushehr, Iran

In charge of blood screening unit

2000-2001

(IBTO) of Boushehr, Iran

Deputy of Director

1999-2000

Research Center of Natural Resources

In charge of Serology & Microbiology lab

Animal affairs related to Serum and Vaccine producing

Razi institute (Boushehr, Iran)

1994-2004

Private medical diagnostic laboratory (Boushehr, Iran)

In charge of Medical Microbiology & Mycology unit, (part time)

1997-1999

Amiralmoamenin (A) Hospital

In charge of Medical Microbiology & Mycology unit, (part time)

(2 years)

(Boushehr, Iran)

1994-1997

Research Center of Natural Resources

In charge of Serology & Microbiology lab

Animal affairs related to Serum and Vaccine producing

Razi institute (Boushehr, Iran)

MAJOR ACHIEVEMENTS

2000

Implementation of QC/ Reference lab of Iranian Blood Transfusion Organization-Boushehr, Iran

1994

Implementation of Serology & Microbiology lab of Research Center of Natural Resources and Animal Affairs-Boushehr, Iran

LABORATORY SKILLS

PCR, Q PCR, Direct Sequencing, Next Generation Sequencing (NGS).

ELISA, Recombinant Immunoblot Assay (RIBA) Test, Western blot, Neutralization test.

Plaque assay.

Techniques used in Diagnostic Bacteriology, Mycology and Parasitology (Culturing, Differentiation, Antibiogram tests). Ames test, Replica plate assay.

Wright, Coombs Wright and 2ME tests. Metabolic serological Tests.

COMPUTER SKILLS

Routine software like Microsoft office, Adobe Illustrator, EndNote, Bioinformatics, Phylogenetic analysis software, Statistical software (SPSS) and internet applications.

LANGUAGE SKILLS

Persian Native language
Arabic B1
English Proficient
Dutch More than B1

HOBBIES

I enjoy playing and watching football, swimming, gardening and going to the cinema

TRAINING

May 2019 GCP, UZ Leuven, Belgium
May 2018 ESCV Workshop Copenhagen, Denmark
Sep- 2010 16th International Bioinformatics Workshop– Baltimore, USA
Feb- 2007 Computational Genomics Workshop, Charles University, Prague, Czech Republic

EDITORIAL MEMBER

2015-present Scientific advisory board of the scientific journal of Iranian Blood Transfusion Organization
2015-present Editorial board of Journal of Virology and Antiviral Research
2012-present Editorial board of Journal of HIV/AIDS and Infectious Diseases (JAID)
2009-present Associated Editor of Hepatitis Monthly

REVIEWER OF FOUNDATION INSTITUTES

2016-present Natural Sciences and Engineering Research Council of Canada (NSERC)
2017-present Cancer Care Manitoba Foundation (CCMF)
2018-present Children Hospital Research Institute of Manitoba CHRIM

SCIENTIFIC MEMBER

2017-present Scientific Advisory Board, Hepatitis global community
2009-present Scientific Advisory Board, Iran Hepatitis Network
2009-present European Society of Virology
2003-present Iranian Society of Virology

SCIENTIFIC AWARDS

2009 “Outstanding Researcher” by Blood Transfusion Research Centre, High Institute for Research and Education in Transfusion Medicine, Iran

MENTORING EXPERIENCE

2014-present Five PhD training students, Co-promotor of one FWO PhD student
2010-present Three Biomedical Master students, Co-promotor and supervision
2008-2015 12 (Rotation training, Master students Biomedical Sciences)

GRANTS

2020 C1, Research Grant of KU Leuven
2019 Research Fellowship grant from GILEAD
2018 ECDC observership grant, Stockholm-2018
2018 Travel grant for 16th ISVHLD, Toronto-2018
2018 Travel grant for ESCV workshop Copenhagen-2018
2018 Research Fellowship grant from GILEAD
2017 Travel grant for ESCV workshop Saint Petersburg-2017
2017 Research Fellowship grant from GILEAD
2016 Research Fellowship grant from GILEAD
2016 FWO Research grant
2016 FWO Postdoctoral fellowship (2016-2019)
2015 Travel grant for The 6th International Tehran Hepatitis Congress. Iran, Tehran 26-29 May 2015
2013 FWO Postdoctoral fellowship (2013-2016)
2011 Travel grant for The 4th International Tehran Hepatitis Congress. Iran, Tehran 23-26 Nov- 2011
2009 Travel grant for ESCV Congress Istanbul-2009
2009-2012 Doctoral scholarship from K.U. Leuven
2006-2008 Doctoral scholarship from Iranian blood transfusion organization (IBTO)
2003 Research grant, Iranian Blood Transfusion Organization
2002 Research grant, Boushehr University of Medical Sciences
1996 Research grant, Research Center of Natural Resources Animal affairs related to Serum and Vaccine producing, Razi institute (Boushehr-Iran)
1994 Research grant, Research Center of Natural Resources Animal affairs related to Serum and Vaccine producing, Razi institute (Boushehr-Iran)

REFERENCES

Professor Dr. Marc Van Ranst
 Professor Dr. Johan Neyts
 Professor Dr. Philippe Lemey
 Professor Dr. Frank Tacke
 Professor Dr. Frederik Nevens
 Professor Dr. Seyed Moaied Alavian
 Professor Dr. Kamran Bagheri Lankarani
 Professor Dr. Ahmad Gharehbaghian
 Professor Dr. Aliakbar Pourfathollah
 Professor Dr. Keivan Zandi
 Professor Dr. Chris Verslype

PUBLICATION LIST

1. Hashemi,SMA, Thijssen M, Hosseini SY, Tabarraei, A, **Pourkarim MR** and Sarvari. Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection. *Archive of Virology*. 2021 May 2;1-20. doi: 10.1007/s00705-021-05070-6.
2. Thijssen M, Tacke, F, Beller, L, Deboutte W, Yinda CK, Nevens F, Laleman W, Van Ranst M and **Pourkarim MR***. Clinical relevance of plasma virome dynamics in liver transplant recipients. *EBioMedicine*. 2020. September, 23;60;103009.
3. **Pourkarim MR***, Thijssen M, Vandamme AM and Van Ranst M. Air conditioning system usage and SARS-CoV-2 Transmission dynamics in Iran. *Medical Hypothesis*. 2020. August, 384-7.
4. Vandamme AM, Nguyen T, Denis M, Kiekens A, Nova Blanco, JR, **Pourkarim MR**, Van Ranst M, Naesens L, Depypere, M, Ronse, M, Peeters K, Van Daele N, Van den Cruyce N, Van Hoof E, Vercauteren, S and Vandermeulen C. Belgium - concerns about coronavirus contact-tracing apps? *Nature*. 2020. 581, 384.
5. Zhang M, Li G, Shang J, Pan C, Zhang M, Yin Z, Xie Q, Peng Y, Mao Q, Xiao X, Jiang Y, Luo K, Xu Y, Ding H, Fan W, Diego V, **Pourkarim MR**, De Clercq E, Wang G, Gong G. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. *Hepatology International*. 2020. Mar;14(2):212-224. doi: 10.1007/s12072-020-10015-3.
6. Thijssen M, Trovão N. S, Mina T, Maes P and **Pourkarim MR***. Novel Hepatitis B virus Subgenotype A8 and Quasi-subgenotype D12 in African-Belgian chronic carriers. *Int Infect Dis*. 2020, Jan 28. pii: S1201-9712(20)30051-5. doi: 10.1016/j.ijid.2020.01.048.
7. Al-Qahtani A. A, **Pourkarim MR**, Trovão N. S, Vergote V, Li G, Thijssen M, Abdo A. A, Sanai F. M, Dela Cruz D, Bohol M. Fe F, Al-Anazi M. R, Al-Ahdal M. N Molecular epidemiology, phylogenetic analysis and genotype distribution of Hepatitis B Virus in Saudi Arabia: Predominance of Genotype D1. *Infect Genet Evol*. 2020, Jan 23, 77:10451.
8. Vaezjalali M, Goudarzi H, Rashidpour S, Davoodbeglou F, Thijssen M, and **Pourkarim MR***. Persons with intellectual disability: a potential reservoir of invasive strains of hepatitis B virus. *Hepatitis Monthly*. 2019, September, 16; 19(9):e85661.
9. Cuypers L, Thijssen M, Shakibzadeh A, Deboutte W, Sarvari J, Sabahi F, Ravanshad M and **Pourkarim MR***. Signature of natural resistance in NS3 protease revealed by deep sequencing of HCV strains circulating in Iran. *Infect Genet Evol*.2019, July 16: 103966.
10. Cuypers L, Thijssen M, Shakibzadeh A, Sabahi F, Ravanshad M and **Pourkarim MR***. Next-generation sequencing for the clinical management of hepatitis C virus infections: Does one test fits all purposes? *Crit Rev Clin Lab Sci*. 2019, July 18: 1-15.
11. **Pourkarim MR***, Thijssen M, Alavian SM, Van Ranst M. Natural disasters pose challenges for hepatitis elimination in Iran. *The Lancet Gastroenterology & Hepatology*. 2019, August 4 (8).581-582.

12. Thijssen M, Lemey P, Amini-Bavil-Olyae S, Dellicour S, Alavian SM, Tacke F, Verslype C, Nevens F and **Pourkarim MR***. Mass Migration to Europe: an Opportunity for the Elimination of Hepatitis B Virus? *The Lancet Gastroenterology & Hepatology*. 2019. April 4(4):315-323.
13. **Pourkarim MR***, Razavi H, Lemey P and Van Ranst M. Iran's hepatitis elimination programme is under threat. *The Lancet*. 2018. 22;392, 1052, September 20.
14. Vrancken B, Alavian SM, Aminy A, Amini-Bavil-Olyae S, and **Pourkarim MR***. Why comprehensive datasets matter when inferring epidemic links or (sub)genotyping. *Infec Genet Evol*. 2018. Aug 16; 65:350-351.
15. Pourkarim M, Van Espen L, Thijssen M, Van Ranst M and **Pourkarim MR***. How adequate social media management supports the Viral Hepatitis Elimination Program. *Hepatitis Monthly*. 2018. May;18(5): e69791.
16. Thijssen M, Van Ranst M, **Pourkarim MR***. Elimination of hepatitis and an update on blood safety. *Hepatitis Monthly*. 2018 March; 18(3) e66577.
17. Mina T, Amini-Bavil-Olyae S, Shirvani-Dastgerdi E, Trova NS, Van Ranst M, **Pourkarim MR***. 15 years fulminant hepatitis B follow-up in Belgium: Viral evolution and signature of demographic change. *Infec Genet Evol*. 2017 Apr, 49:221-225.
18. Shirvani-Dastgerdi E, **Pourkarim MR**, Herbers U, Amini-Bavil-Olyae S, Yagmur E, Alavian SM, Trautwein C, Tacke F. Hepatitis Delta Virus endorses the selection of Hepatitis B Virus mutants in vivo and functionally impacts their replicative capacity in vitro. *Clinical Microbiology and Infection*. 2016 Jan;22(1):98.e1-98.e6. doi: 10.1016/j.cmi.2015.09.020.
19. Mina T, Amini-Bavil-Olyae S, Dekervel J, Verslype C, Nevens F, Maes P, Tacke F, Van Ranst M, **Pourkarim MR***. A rare case of HBV genotype fluctuation (shifting and reversion) after liver transplantation. *Journal of Clinical Virology*. 2015, Oct;71:93-7.
20. Mina T, Amini-Bavil-Olyae S, Tacke F, Maes P, Van Ranst M, **Pourkarim MR***. Genomic Diversity of Hepatitis B Virus Infection Associated With Fulminant Hepatitis B Development. *Hepatitis Monthly*. 2015, Jun 23 (15)(6)e29477.
21. Pineda-Peña AC, Faria NR, Mina T, Amini-Bavil-Olyae S, Alavian SM, Lemey P, Maes P, Van Ranst, M and **Pourkarim MR***. Epidemiological history and genomic characterization of non-D1 HBV strains identified in Iran. *Journal of Clinical Virology*. 2015, 63: 38-41.
22. **Pourkarim MR**, Amini-Bavil-Olyae S, Kurbanov F, Van Ranst M, Tacke F. Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions. *World Journal of Gastroenterology*. 2014, Jun: 20 (23): 7152-68.
23. **Pourkarim MR**, Vergote V, Amini-Bavil-Olyae S, Sharifi Z, Sijmons S, Lemey P, Maes P, Alavian SM, Van Ranst M. Molecular characterization of hepatitis B virus (HBV) strains circulating in the northern coast of the Persian Gulf and its comparison with worldwide distribution of HBV subgenotype D1. *Journal of Medical Virology*. 2014, May: 86(1): 745-57.
24. **Pourkarim MR**, Sharifi Z, Amini-Bavil-Olyae S, Soleimani A, Elsadegh Fakhr, Sijmons S, Vercauteren J, Karimi G, Lemey P, Maes P, Alavian SM, Van Ranst M. Evolutionary analysis of HBV "S" antigen genetic diversity in Iranian blood donors: A nationwide study. *Journal of Medical Virology*. 2014, Jan: 86(1): 144-55.
25. Elsadegh Fakhr A, **Pourkarim MR**, Maes P, Atta AH, Marei A, Azab M and Van Ranst M. Hepatitis C Virus NS5B Sequence-Based Genotyping Analysis of Patients from the Sharkia Governorate, Egypt. *Hepatitis Monthly*. 2013, Dec17; 13 (12):1-5.
26. Nahar S, Afrad MH, Begum N, Al-Mamun F, Sarker AK, Das SK, Faruque ASG, **Pourkarim MR**, Choudhuri MSK, Azim T, Rahman M. High prevalence of noroviruses in hospitalized diarrheal patients in Bangladesh, 2011. *Journal of Infection in Developing Countries*. 2013, 7(11): 892-896.

27. Mustafizur R, Chowdhury E, Reza M, Alam MS, Sarker MS, Afrad MH, Alam M, Rahman Z, **Pourkarim MR** and Tasnim A. Genetic Characterization of Hepatitis C Viruses in HIV Positive People who Inject Drugs, Dhaka, Bangladesh. *Journal of AIDS and Clinical Research*. 2012, 3(7): 1-2.
28. Amini-Bavil-Olyae S and **Pourkarim MR***. How can a novel molecular diagnostic assay instill confidence in researchers and encourage its future use? *Hepatitis Monthly*. 2012, 12(4):292-3.80(3).
29. Amini-Bavil-Olyae S, Maes P, Van Ranst M and **Pourkarim MR***. Providing Strong Evidence of Nosocomial Outbreak of Hepatitis B virus infection. *Journal of Hospital Infection*. January 2012, 80(3):269-70.
30. **Pourkarim MR** and Van Ranst M. Guidelines for the detection of a common source of hepatitis B virus infection. *Hepatitis Monthly*. 2011, 11(10):783-5.
31. **Pourkarim MR**, Lemey P, Amini-Bavil-Olyae S, Hospie L, Verbeeck J, Rahman M, Maes P, Vanwijngaerden E, Nevens F, and, Van Ranst M. Phylogenetic analysis and molecular characterization of strains circulating in HIV/HBV co infected patients with occult and overt infections in Belgium. *Journal of Medical Virology*. 2011, 83(11): 1876-84.
32. **Pourkarim MR**, Amini-Bavil-Olyae S, Lemey P, Maes P, Van Ranst M. HBV subgenotype misclassification expands quasi-subgenotype A3. *Journal of clinical Microbiology and Infection*. 2011, 17(6): 947-9).
33. **Pourkarim MR**, Van Ranst M. Letter-to-Editor over: A study of genotypes, mutants and nucleotide sequence of Hepatitis B virus in Pakistan. *Hepatitis Monthly*. 2011 11(4):292-4.
34. Farjana S, Rahman HN, Moni S, Karim M, **Pourkarim MR**, Azim T, Rahman M. Clinical presentation and molecular characterization of group B rotaviruses in diarrhea patients in Bangladesh. *Journal of Medical Microbiology*. 2010, 60(pt4):529-36.
35. Amini-Bavil-Olyae S, **Pourkarim MR**, Schaefer S, Mahboudi F, Van Ranst M, Adeli A., Trautwein C and Tacke F. Single-step real-time PCR to quantify hepatitis B virus and distinguish genotype D from non-D genotypes. *Journal of Viral Hepatitis*. 2010, 18(4):300-4.
36. **Pourkarim MR**, Amini-Bavil-Olyae S, Lemey P, Maes P, Van Ranst M. Are hepatitis B virus "subgenotypes" defined accurately? *Journal of Clinical Virology*. 2010, 47(4):356-360.
37. **Pourkarim MR**, Amini-Bavil-Olyae S, Verbeeck J, Lemey P, Rahman M, Zeller M, Maes P, Nevens F, Van Ranst M. Molecular Evolutionary Analysis and Mutational Pattern of Full-Length genomes Hepatitis B Virus Isolated from Belgian Patients with Different Clinical Manifestations. *Journal of Medical Virology*, 2010, 82(3):379-89.
38. **Pourkarim MR**, Lemey P, Amini-Bavil-Olyae S, Maes P, Van Ranst M. Novel hepatitis B virus subgenotype A6 in African-Belgian patients. *Journal of Clinical Virology*. 2010, 47(1):93-6.
39. Demeester R, Bottieau E, Van Esbroeck M, **Pourkarim MR**, Maes P, Clement J. Hantavirus nephropathy as a pseudo-import pathology from Ecuador. *European Journal of Clinical Microbiology and Infectious Diseases*. 2010, 29(1):59-62.
40. **Pourkarim MR**, Verbeeck J, Rahman M, Amini-Bavil-Olyae S, Forier AM, Lemey P, Maes P, Van Ranst M. Phylogenetic analysis of hepatitis B virus full-length genomes reveals evidence for a large nosocomial outbreak in Belgium. *Journal of Clinical Virology*. 2009, 46(1):61-8.
41. Verbeeck J, Van Assche G, Ryding J, Wollants E, Rans K, Vermeire S, **Pourkarim MR**, Noman M, Dillner J, Van Ranst M, Rutgeerts P. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? *Gut*. 2008, 57(10):1393-7.

42. Rabbani Khorasgani M, Esmaceli H, **Pourkarim MR**, Mankhian AR, Zahraei Salehi T. Anti-*brucella* antibodies in blood donors in Boushehr, Iran. *Comparative Clinical Pathology*. 2008, 17(4): 267-269.
43. **Pourkarim MR**, Zandi K, Ardeshtir Davani N, Pourkarim HR, Amini-Bavili-Olyae S. An aberrant high prevalence of hepatitis B infection among Afghans residing in one of the Boushehr refugee camps (Dalaki Camps) in the southwest of Iran. *International Journal of Infectious Diseases*. 2008, 12 (1):101-2.
44. **Pourkarim MR**, Khamisipour GR, Zandi K, Roustaei MR. Prevalence of HTLV-I & II antibodies in blood donors in Boushehr Province. *Iranian South Medical Journal*. 2004, 6(2):161-164.
45. **Pourkarim MR**, Khamisipour GR, Zandi K, Davani NA. Seroepidemiological investigation of HTLV I/II infection among multiple transfused (Thalassemic, Hemophilic and Hemodialysis) patients in Boushehr province. *Scientific Journal of Iranian Blood Transfusion Organization*, 2005, 2(4):99-104.
46. **Pourkarim MR**, Zandi K, Khamisipour GR. Seroepidemiological investigation of HTLV I/II infection among blood donors of Boushehr province. *Tebe Jonoob* (Persian), 2003, 36:83-88.
47. **Pourkarim MR**, Fakhri, Heidari, H, Sedighi MA. Impact of *Rhizobium* strains on growth and stabilization of nitrogen alfalfa cultivars in Boushehr province. *Research & Building* (Scientific Persian Journal). 2000, 8(10): 351-53.
48. Pourebrahim MR, Hooshmand Rad P and **Pourkarim MR***. Assigning Eimeria species of goat in Boushehr Province. *Agricultural and Natural Resources Research* (Scientific Persian Journal). 2000, 4(3): 115-119.
49. **Pourkarim MR**, Zoghi E. Serebacteriology of Human-livestock brucellosis in Boushehr province. *Iranian Journal of Medical Sciences* (Persian). 1999, 2(1):54-58.
50. Moradi A, Mansurian AR, Ghaemi, E, Kalavi KH, Marjani A, Sanei Moghadam, E, Agliano Am, **Pourkarim MR**, Khamisi Pour GR, Hajjani GR, Tahmasebi R, Davan AN, Sotoodeh M, Tabei SZ, Tavanai Sani a. Serologic prevalence of HTLV-1 among blood donors in Mashhad (Northeast of Iran). *Journal of Applied Sciences*. 1998, 8(2): 54-59.
51. **Pourkarim MR**, Abbassi A Khajeh, GH. Serological evaluation of brucellosis in single hoofed animals of nomads in Boushehr province. *Iran Veterinary Journal* (Persian). 1998, 24(9):29-33.

ABSTRACTS

ORAL PRESENTATIONS

1. Al-Qahtani A. A, **Pourkarim MR**, Trovão N. S, Vergote V, Li G, Thijssen M, Abdo A. A, Sanai F. M, Dela Cruz D, Bohol M. Fe F, Al-Anazi M. R, Al-Ahdal M. N. Molecular epidemiology and phylogenetic analysis of hepatitis B virus in Saudi Arabi. 21th Annual Meeting of the European Society for Clinical Virology, Athens, Greece, 23-26 September 2018.
2. **Pourkarim MR**. Immigration and HBV control in Europe. ESCV workshop Copenhagen-Denmark. 29-30 May 2018.
3. Vaezjalali M, Goudarzi H, Rashidpour S, Davoodbeglou F, Thijssen M, and Pourkarim MR. Hepatitis B infection in Iranian institutionalized mentally retarded patients. 7th International Tehran Hepatitis Conference. September 6-8, 2017.
4. **Pourkarim MR**. HBV genotyping and subgenotyping misclassification. 6th International Tehran Hepatitis Conference/EASL. May 27-29, 2015.
5. Nídia Sequeira Trovão, Andrea-Clemencia Pineda-Peña, Samad Amini-Bavil-Olyae, Thomas Mina, Philippe Lemey, Piet Maes, Marc Van Ranst, **Pourkarim MR**. Phylodynamic reconstruction of Hepatitis B virus D1, D2 and D3 strains in Iran. 6th International Tehran Hepatitis Conference/EASL. May 27-29, 2015.

6. **Pourkarim MR.** The role of molecular analysis in the detection of a common source of hepatitis B virus infection. The 4th International Tehran Hepatitis Congress. Iran, Shiraz 23-26 November 2011.
7. **Pourkarim MR.** Hepatitis B virus genotyping, subgenotyping: new challenge. The 4th International Tehran Hepatitis Congress. Iran, Tehran 23-26 November 2011.
8. **Pourkarim MR.** Van Ranst M. computational Biology, Workshop. The 4th International Tehran Hepatitis Congress. Iran, Shiraz 23-26 November 2011.
9. **Pourkarim MR.** Verbeeck J, Rahman M, Amini-Bavil-Olyae S, Forier AM, Lemey P, Maes P, Van Ranst M. Phylogenetic analysis of hepatitis B virus full-length genomes reveals evidence for a large nosocomial outbreak in Belgium, 14th Annual Meeting of the European Society for Clinical Virology, Istanbul, Turkey, 27-30 September 2009. Published in: *Journal of Clinical Virology*. 2009. 46(1): S8-S8.
10. **Pourkarim MR.** Zandi K, Khamisipour GR, Davani NA. Seroepidemiological investigation of HTLV I/II infection among multiple transfused (Thalassemic, Hemophilic and Hemodialysis) patients in Boushehr province. 2nd Iranian Congress on Virology, Tehran, Iran, 13-15 February 2004.

POSTER PRESENTATIONS

11. Thijssen M, Beller L, Yinda K. C, Deboutte W, Maes P. Matthijnsen J, Van Ranst M, **Pourkarim MR.** Genetic diversity of anelloviruses in the blood virome. 23rd International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology (VEME). Berlin, Germany. August 26-31, 2018.
12. Thijssen M, Beller L, Yinda K. C, Deboutte W, Maes P. Matthijnsen J, Van Ranst M, **Pourkarim MR.** Eukaryotic virome profile interactions in liver transplant recipients infected by HBV. The 16th International Symposium on Viral Hepatitis and Liver Diseases, ISVHLD. Toronto, Canada, Jun 14-17, 2018. Published in *Journal of Viral Hepatitis*. 2015. 25:S1, P125-125.
13. Vaezjalali M, Mousavi MJ, Naseri K, **Pourkarim MR.** Genome recombination among hepatitis b viruses derived from intravenous drug users, the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Madrid-Spain. April 21-24, 2018.
14. Mina T, Amini-Bavil-Olyae S, Dekervel J, Verslype C, Nevens F, Maes P, Tacke F, Van Ranst M and **Pourkarim MR.** HBV genotype fluctuation (shifting and reversion) after liver transplantation. 15th International Symposium on Viral Hepatitis and Liver Diseases. Berlin, Germany. Jun 26-28, 2015. Published in *Journal of Viral Hepatitis*. 2015. 22:S1, P45-45
15. Li G, Amini-Bavil-Olyae S, Lemey P, Maes P, Van Ranst M, **Pourkarim MR.** HBV genome-wide diversity from the world population perspective. 6th International Tehran Hepatitis Conference/EASL. May 27-29, 2015.
16. **Pourkarim MR.** Lemey P, Amini-Bavil-Olyae S, Hospie L, Maes P, Van Ranst M. Phylogenetic analysis and molecular characterization of strains circulating in HIV/HBV co infected patients with occult and overt infections in Belgium. 16th International Bioinformatics Workshop 2010 – Baltimore, USA-September 2010.
17. Maes P, **Pourkarim MR.** Coen N, Van Ranst M. Oseltamivir-resistant influenza A/H1N1 viruses in Belgium, during the 2007-2008 influenza season, 14th Annual Meeting of the European Society for Clinical Virology, Istanbul, Turkey, 27-30 September 2009. Published in *Journal of Clinical Virology*. 2009. 46 page S19.
18. **Pourkarim MR.** Zandi P, Khamisipoor G. Evaluation of viral hepatitis B infection markers status in Afghan population living in Dalaki in Bousher Province. 2nd Iranian Congress on Virology, Tehran, Iran, 13-15 February 2004.
19. **Pourkarim MR.** Zandi P. Seroepidemiological investigation of HTLV I/II infection among multiple transfused (Thalassemic, Hemophilic and Hemodialysis) patients in Boushehr province. 2nd Iranian Congress on Virology, Tehran, Iran, 13-15 February 2004.

BOOK-CO-AUTHORSHIP

The Human Gut-Liver-Axis in Health and Disease, ISBN: 978-3-319-98889-4,
Chapter: The Role of the Virome in the Gut-Liver Axis

TEACHING EXPERIENCE

- 2020-Oct Virtual Lecturer – **Convalescent Plasma therapy & COVID-19** (4h/year), Tarbiat Modares, Tehran, Iran
- 2020-Sep Virtual Lecturer – **Convalescent Plasma therapy & COVID-19** (4h/year), University of Medical Sciences, Urmie, Iran
- 2021-April Virtual Lecturer – **Covid-19 pandemic and challenges of diagnosis and vaccination in Iran** (3 h/year), Immunology Today, Tehran, Iran.
- 2000–2006 Lecturer – **Blood safety (32h/year)**, Blood Transfusion Organization, Iran
- 2000–2006 Lecturer – **Blood screening (32h/year)**, Blood Transfusion Organization, Iran
- 2000–2006 Lecturer – **Virology in Blood Bank (32h/year)**, Blood Transfusion Organization, Iran
- 2000–2006 Lecturer – **Quality control in Blood Bank (64h/year)**, Blood Transfusion Organization, Iran
- 2000–2006 Lecturer – **Confirmatory test in Blood screening (64h/year)**, Blood Transfusion Organization, Iran
- 2000–2006 Lecturer – **Emerging infectious diseases & blood safety (64h/year)**, Blood Transfusion Organization, Iran